Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients

Breast Cancer Research and Treatment

Volumn 82, Issue 2, 2003, Pages 103-111

  Ellmen J ^a,b   Hakulinen, P ^b   Partanen, A ^b   Hayes, D F ^c  

^a Clinical Development   (Finland)

^b ORION CORPORATION   (Finland)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Breast cancer; Hormonal effects; Postmenopausal; Tamoxifen; Toremifene

Indexed keywords

ANTITHROMBIN III; ASPARTATE AMINOTRANSFERASE; ESTRADIOL; ESTROGEN; FOLLITROPIN; LUTEINIZING HORMONE; SEX HORMONE BINDING GLOBULIN; TAMOXIFEN; TOREMIFENE;

ADULT; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOAVAILABILITY; BREAST CARCINOMA; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ESTRADIOL BLOOD LEVEL; ESTROGEN ACTIVITY; FEMALE; FOLLITROPIN BLOOD LEVEL; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IN VIVO STUDY; LUTEINIZING HORMONE BLOOD LEVEL; MULTICENTER STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TISSUE SPECIFICITY; VAGINA CYTOLOGY; VAGINA EPITHELIUM;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTITHROMBIN III; ASPARTATE AMINOTRANSFERASES; BREAST NEOPLASMS; CENTRAL NERVOUS SYSTEM DISEASES; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; HYPERCALCEMIA; LUTEINIZING HORMONE; MIDDLE AGED; PENTOXIFYLLINE; POSTMENOPAUSE; SEX HORMONE-BINDING GLOBULIN; TAMOXIFEN; TREATMENT OUTCOME; VAGINA;

EID: 0345257213     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BREA.0000003957.54851.11     Document Type: Article

References (43)

1. Anttila M, Valavaara R, Kivinen S, Mäenpää J: Pharmacokinetics of toremifene. J Steroid Biochem 36: 249-252, 1990
2. Bergman L, Beelen MLR, Gallee MPW, Hollema H, Benraadt J, van Leeuwen FE and the Comprehensive Cancer Centers' ALERT Group: Lancet 356: 881-887, 2000
3. Bratherton DG, Brown CH, Buchanan R, Hall V, Kingsley Pillers EM, Wheeler TK, Williams CJ: A comparison of two doses of tamoxifen (Nolvadex*) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd. Br J Cancer 50: 199-205, 1984
4. Curtis ER, Boice JD, Shiner DA, Hankey BF, Fraumeni Jr JF: Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst 88: 832-834, 1997
5. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for breast Cancer. An overview of the randomized trials. Lancet 351: 1451-1467, 1998
6. Ellmén J, Werner D, Hakulinen P, Keiling R, Fargeot P, Falkson G, Bezwoda WR: Dose-dependent hormonal effects of toremifene in postmenopausal breast cancer patients. Cancer Chemother Pharmacol 45: 402-408, 2000
7. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM, Other NSABP Contributors: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the national surgical adjuvant breast and bowel project (NSABP) B-14. J Natl Cancer Inst 86: 527-537, 1996
8. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschênes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AHG, Feldman MI, Farrar W, Evans J, Lickley HL: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor positive tumors. J Natl Cancer Inst 88: 1529-1542, 1996
9. Fisher B, Costantino JP, Wickerham DL, Redmond Carol K, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N, and the other National Surgical Adjuvant Breast and Bowel Project Investigators: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371-1388, 1998
10. Fornander T, Cedermark B, Mattsson A, Skoog L, Theve T, Askergren J, Rutqvist L, Glas U, Silversward C, Somell A, Wilking N, Hjalmar M: Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1: 117-120, 1989
11. Gershanovich M, Garin A, Baltina D, Kurvet A, Kangas L, Ellmén J: A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Breast Cancer Res Treat 45: 251-262, 1997
12. Gershanovich M, Hayes DF, Ellmén J, Vuorinen J: High dose toremifene v.s. tamoxifen in postmenopausal advanced breast cancer. Oncology 11(Suppl 4): 29-36, 1997
13. Goldhirsch A, Wood WC, Senn H-J, Click JH, Gelber RD: Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 87: 1441-1445, 1995
14. Gundersen S: Toremifene, a new antiestrogenic compound in the treatment of metastatic mammary cancer. A phase II study. J Steroid Biochem 36: 233-234, 1990
15. Hayes DF, Van Zyl JA, Hacking A, Goedhals L, Bezwoda WR, Mailliard JA, Jones SE, Vogel CL, Berris RF, Shemano I, Schoenfelder J: Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13: 2556-2566, 1995
16. Hietanen T, Hakala T, Baltina D, Johansson R, Numminen S, Helle L, Valavaara R, Thölix E: Open phase II study of high-dose toremifene as first-line therapy for advanced breast cancer. Oncology 11 (Suppl 4): 37-40, 1997
17. Holli K, Valavaara R, Blanco G, Kataja V, Hietanen P, Flander M, Pukkala E, Joensuu H for the Finnish Breast Cancer Group: Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. J Clin Oncol 18: 3487-3494, 2000
18. Homesley HD, Shemano I, Gams R, Harry DS, Hickox PG, Rebar RW, Bump RC, Mullin TJ, Colston Wentz A, O'Toole RV, Lovelace JV, Lyden C: Antiestrogenic potency of toremifene and tamoxifen in postmenopausal women. Am J Clin Oncol 16: 117-122, 1993
19. Joensuu H, Holli K, Oksanen H, Valavaara R: Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer. Breast Cancer Res Treat 63: 225-234, 2000
20. Jordan VC: Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer. Annu Rev Pharmacol Toxicol 35: 195-211, 1995
21. Kangas L, Kallio S, Blanco G, Grönroos M, Kallio S, Karjalainen A, Perilä M, Södervall M, Toivola R: A new triphenylethylene compound, FC-1157a. II. Antitumor effects. Cancer Chemother Pharmacol 17: 109-114, 1986
22. Kangas L: Agonistic and antagonistic effects of antiestrogens in different target organs. Acta Oncol 31: 143-146, 1992
23. Kendall ME, Rose DP: The effects of diethylstilbesterol, tamoxifen, and toremifene on estrogen-inducible hepatic proteins and estrogen receptor proteins in female rats. Toxicol Appl Pharmacol 114: 127-131, 1992
24. van Leeuwen FE, Benraadt J, Coebergh JWW, Kiemeney LALM, Gimbrère CHF, Otter R, Schouten LJ, Damhuis RAM, Bontenbal M, Diepenhorst FW, van den Belt-Dusebout AW, van Tintere H: Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343: 448-452, 1994
25. Marttunen MB, Hietanen P, Tiitinen A, Ylikorkala O: Comparison of effects of tamoxifen and toremifene on bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab 83: 1158-1162, 1998
26. Modig H, Borgström S, Nilsson I, Westman G: Phase II clinical study of toremifene in patients with metastatic breast cancer. Preliminary communication. J Steroid Biochem 36: 235-236, 1990
27. Mouridsen H, Palshof T, Patterson J, Battersby L: Tamoxifen in advanced breast cancer. Cancer Treat Rev 5: 131-141, 1978
28. Mäenpää J, Ellmén J, Pasanen T, Kaukonen M: Correspondence: effect of the antiestrogens tamoxifene, Toremifene, and ICI 182,780 on endometrial cancer growth. J Natl Cancer Inst 91: 972, 1999
29. Osborne CK: Receptors. In: Harris J, Hellman S, Henderson I et al (eds) Breast Diseases. JB Lippincott, Philadelphia, 1991, pp 301-325
30. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, Tidy A, Viggers J, Davey J: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital: tamoxifen randomized chemoprevention trial. Lancet 352: 98-101, 1998
31. Pukkala E, Maijanen S, Kyyrönen P, Sankila R, Holli K: Tamoxifen and toremifene treatment of breast cancer and risk of subsequent endometrial cancer - a population-based case-control study. Manuscript, 2001
32. Pyrhönen S, Valavaara R, Heikkinen M, Rissanen P, Blanco G, Nordman E, Holsti RL, Hajba A: Treatment of advanced breast cancer with 20 mg toremifene, a phase II study. Preliminary communication. J Steroid Biochem 36: 227-228, 1990
33. Pyrhönen S, Valavaara R, Modig H, Pawlicki M, Pienkowski T, Gundersen S, Bauer J, Westman G, Lundgren S, Blanco G, Mella O, Nilsson I, Hietanen T, Hindy I, Vuorinen J, Hajba A: Comparison of toremifene and tamoxifen in postmenopausal patients with advanced breast cancer: a randomised double blind, the 'Nordic' phase III study. Br J Cancer 76: 270-277, 1997
34. Pyrhönen S, Ellmén J, Vuorinen J, Gershanovich M, Tominaga T, Kaufmann M, Hayes DF: Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat 56: 133-143, 1999
35. Rosner WA: A simplified method for the quantitative determination of testosterone-estradiol-binding globulin activity in human plasma. J Clin Endocrinol Metab 34: 983-988, 1971
36. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N: Adjuvant tamoxifen therapy for early stage breast cancert and second primary malignancies. J Natl Cancer Inst 87: 645-651, 1995
37. Saarto T, Blomqvist C, Ehnholm C, Taskinen M-R, Elomaa I: Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol 14: 429-433, 1996
38. Saarto T, Blomqvist C, Välimäki M, Mäkelä P, Sarna S, Elomaa I: Clodronate improves bone mineral density in postmenopausal breast cancer patients treated with antioestrogens. Br J cancer 75: 602-605, 1997
39. di Salle E, Zaccheo T, Ornati G: Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat. J Steroid Biochem 36: 203-206, 1990
40. Számel I, Hindy I, Vincze B, Eckhardt S, Kangas L, Hajba A: Influence of toremifene on the endocrine regulation in breast cancer patients. Eur J Cancer 30A: 154-158, 1994
41. Valavaara R, Pyrhönen S, Heikkinen M, Rissanen P, Blanco G, Thölix E, Nordman E, Taskinen P, Holsti L, Hajba A: Toremifene, a new antiestrogenic Compound, for treatment of advanced breast cancer. Phase II study. Eur J Cancer Clin Oncol 24: 785-790, 1988
42. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, Rotmensz N, Boyle P on behalf of the Italian Tamoxifen Prevention Study: Prevention of breast cancer with tamoxifen. Preliminary findings from the Italian randomized trial among hysterectomized women. Lancet 352: 93-97, 1998
43. Wolf DM, Jordan VC: Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice. Breast Cancer Res Treat 31: 117-127, 1994